title: Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma.
abstract: OBJECTIVE
  This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of 131I for patients with thyroid carcinoma.
  
  
  METHODS
  In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of 131I, sex, age, 131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses.
  
  
  RESULTS
  Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache.
  
  
  CONCLUSIONS
  Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.
authors.affiliation: Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, Japan. happyman@nmd.m.kanazawa-u.ac.jp
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Kita
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Seigo
authors.initials: S
authors.lastname: Kinuya
authors.forename: Junichi
authors.initials: J
authors.lastname: Taki
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nakajima
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Michigishi
authors.forename: Norihisa
authors.initials: N
authors.lastname: Tonami
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015984:Causality; D015897:Comorbidity; D004307:Dose-Response Relationship, Radiation; D004487:Edema / Q000453:epidemiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D010146:Pain / Q000453:epidemiology*; D011832:Radiation Injuries / Q000453:epidemiology*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D017678:Sex Distribution; D013964:Thyroid Neoplasms / Q000453:epidemiology* / Q000532:radiotherapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals